Success Metrics

Completion Rate
0%(0/2)
Active Trials
1(33%)
Terminated
2(67%)

Phase Distribution

Ph phase_2
1
33%
Ph phase_1
2
67%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Terminated(2)

Detailed Status

Terminated2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (66.7%)
Phase 21 (33.3%)

Trials by Status

recruiting133%
terminated267%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_1

PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

NCT04396873
terminatedphase_1

Novel PET Radioligand as an Inflammatory Biomarker in Musculoskeletal Conditions

NCT03912428
terminatedphase_2

PET Imaging of Cyclooxygenase in Multiple Sclerosis

NCT05062083

Clinical Trials (3)

Showing 3 of 3 trials
NCT04396873Phase 1

PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

Recruiting
NCT03912428Phase 1

Novel PET Radioligand as an Inflammatory Biomarker in Musculoskeletal Conditions

Terminated
NCT05062083Phase 2

PET Imaging of Cyclooxygenase in Multiple Sclerosis

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3